6.5 C
New York
Thursday, October 21, 2021

FDA backs effectiveness of Johnson & Johnson single-shot vaccine with 66.1%

Must Read

Chronic Pain: New painkiller technique without side effects and drug addiction

Innovative non-pharmacological pain management practice developed by scientists - This is how the technique works

Experts identify a new drug that can help diabetic patients recover faster after heart attack

A new study by the University of Oxford's researchers has found a drug that may help repair heart function in...

Study says this drink could reduce death risk from chronic liver disease by 49%

Chronic liver disease is also known as the progressive reduction of liver function over a period of...
Aakash Molpariya
Aakash started in Nov 2018 as a writer at Revyuh.com. Since joining, as writer, he is mainly responsible for Software, Science, programming, system administration and the Technology ecosystem, but due to his versatility he is used for everything possible. He writes about topics ranging from AI to hardware to games, stands in front of and behind the camera, creates creative product images and much more. He is a trained IT systems engineer and has studied computer science. By the way, he is enthusiastic about his own small projects in game development, hardware-handicraft, digital art, gaming and music. Email: aakash (at) revyuh (dot) com

The FDA vaccine advisory committee will now be the one that, based on this report, will decide this Friday if the vaccine could be implemented with the other two already authorized: Pfizer and Moderna.

A panel from the US Food and Drug Administration (FDA) confirmed on Wednesday the effectiveness and safety data of the Johnson & Johnson (J&J) vaccine against covid-19, which requires a single injection, with which its emergency authorization to incorporate it into the vaccination campaign could be imminent.

The FDA’s vaccine advisory committee will now be the one that, based on this report and the data provided by Johnson & Johnson, will decide this Friday if the vaccine could be implemented with the other two already authorized Pfizer / BioNTech and Moderna vaccine.

Earlier this month, Johnson & Johnson said that clinical trial data indicates that its Covid-19 vaccine has overall effectiveness in immunizing against the disease of 66%; 72% in tests carried out in the United States; 66% in Latin America, and 64% in South Africa, where a more resistant variant has spread.

Trials have shown that the vaccine prevents 86% of serious cases in the United States and 82% in Latin America, which in practice would mean that it is highly effective in preventing hospitalizations and deaths from the SARS-CoV-2 coronavirus.

The fact that this vaccine is intended to be administered in a single injection, unlike those of Pfizer and Moderna, which require two appointments, makes it one of the most anticipated, as it would speed up the vaccination campaign.

The FDA believes that it is proven that the new vaccine is highly effective in preventing serious cases and deaths and should contain the spread of the disease, which has claimed more than half a million lives in the United States in just over a year.

The Johnson & Johnson vaccine could get emergency approval this Friday, announcing the decision on Saturday, and immediately begin distribution across the country to the hundreds of vaccination centers that have already begun to inoculate the older population and other risk groups.

The new vaccine can be stored in ordinary refrigerators for at least three months, making it logistically easier to handle than from Pfizer and Moderna, which require more extreme subzero temperatures but have a percentage of efficacy higher, up to 95%.

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -